Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis.
Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Miyake Y, et al. Among authors: ikeda h. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1197-205. doi: 10.1111/j.1365-2036.2006.03113.x. Aliment Pharmacol Ther. 2006. PMID: 17014578 Free article.
A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis.
Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T, Shoji B, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Yamamoto K. Nishida T, et al. Among authors: ikeda h. J Gastroenterol Hepatol. 2008 May;23(5):794-803. doi: 10.1111/j.1440-1746.2007.05240.x. Epub 2007 Dec 14. J Gastroenterol Hepatol. 2008. PMID: 18086120 Clinical Trial.
Lamivudine treatment improves the prognosis of fulminant hepatitis B.
Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, Kobashi H, Sakaguchi K, Shiratori Y. Miyake Y, et al. Among authors: ikeda h. Intern Med. 2008;47(14):1293-9. doi: 10.2169/internalmedicine.47.1061. Epub 2008 Jul 15. Intern Med. 2008. PMID: 18628576 Free article.
Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis.
Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K. Miyake Y, et al. Among authors: ikeda f, ikeda h. Hepatol Res. 2009 Mar;39(3):241-6. doi: 10.1111/j.1872-034X.2008.00454.x. Epub 2008 Nov 26. Hepatol Res. 2009. PMID: 19054143
Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience.
Tanioka D, Iwasaki Y, Araki Y, Osawa T, Ikeda H, Ando M, Kobashi H, Sakaguchi K, Shiratori Y, Yamamoto K. Tanioka D, et al. Among authors: ikeda h. Liver Int. 2009 May;29(5):721-9. doi: 10.1111/j.1478-3231.2008.01964.x. Epub 2009 Jan 6. Liver Int. 2009. PMID: 19141025 Clinical Trial.
Clinical features of type 1 autoimmune hepatitis in adolescence and early adulthood.
Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Sakaguchi K, Ando M, Yamamoto K. Miyake Y, et al. Among authors: ikeda f, ikeda h. Hepatol Res. 2009 Aug;39(8):766-71. doi: 10.1111/j.1872-034X.2009.00510.x. Epub 2009 Apr 3. Hepatol Res. 2009. PMID: 19473431
Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.
Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, Kobashi H, Kobatake T, Tanaka R, Tomita M, Senoh T, Kawaguchi M, Shimoe T, Manabe K, Kita K, Shimamura J, Sakaguchi K, Shiratori Y. Iwasaki Y, et al. Among authors: ikeda h. Liver Int. 2004 Dec;24(6):603-10. doi: 10.1111/j.1478-3231.2004.0956.x. Liver Int. 2004. PMID: 15566511
4,437 results